Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354261 · ClinicalTrials.gov registry record · Phase 2
Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
A Phase 2 study of Basal Cell Carcinoma in Basal Cell Nevus Syndrome, sponsored by HedgePath Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 5
- Study locations
NCT02354261 is a Phase 2 study of Basal Cell Carcinoma in Basal Cell Nevus Syndrome that has completed, run by HedgePath Pharmaceuticals. The registered enrollment target is 38 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT02354261, a Phase 2 study of Basal Cell Carcinoma in Basal Cell Nevus Syndrome, has completed, sponsored by HedgePath Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 5
- Study locations
Study Summary
The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.
Conditions Studied
Interventions
- DRUG SUBA-Itraconazole
Study Locations (5)
California
- Dermatology Specialists, Inc - Oceanside
Florida
- Ameriderm Research - Ormond Beach
Michigan
- Grekin Skin Institute - Warren
New York
- Stony Brook University - East Setauket
Pennsylvania
- Penn State Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2015-08-07 |
| Est. Completion | 2019-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02354261
The ClinicalTrials.gov registry entry for NCT02354261 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HedgePath Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Basal Cell Carcinoma in Basal Cell Nevus Syndrome appearing as the primary indexed condition, and to 1 intervention - of which SUBA-Itraconazole is the first listed.
NCT02354261 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT02354261 about?
NCT02354261 is a clinical study titled "Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)". The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.
What is the current status of trial NCT02354261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2015-08-07. Estimated completion is 2019-03.
What conditions does trial NCT02354261 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma in Basal Cell Nevus Syndrome.
What interventions are being tested in trial NCT02354261?
The interventions under investigation include: SUBA-Itraconazole (DRUG).
Who is sponsoring clinical trial NCT02354261?
This trial is sponsored by HedgePath Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02354261 being conducted?
This trial has 5 study locations across California, Florida, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.